Recent Updates
Recently added Catalysts
ORGO Negative Sentiment Score: 30/100

ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Organogenesis Holdings, Inc. on behalf of long-term stockholders following a class action complaint related to potential breaches of fiduciary duties by the company's board. The investigation stems from an allegation that Organogenesis improperly billed the federal government approximately $250 million annually. A previous report had already led to a significant drop in the company's stock price. Long-term stockholders who have information or questions regarding their rights are encouraged to contact the firm for further assistance.

Market Sentiment Analysis

CONCERNS & RISKS

  • Bragar Eagel & Squire is investigating potential claims against Organogenesis, indicating possible misconduct.
  • A class action complaint has been filed, suggesting serious concerns over the company's operations.
  • The company was alleged to have been improperly billing the federal government for large amounts annually.
  • Previous reports have indicated a significant drop in stock price linked to these allegations.

Full Press Release Details

NEW YORK, Jan. 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQ: ORGO) on behalf of long-term stockholders following a class action complaint that was filed against Organogenesis on December 10, 2021 with a Class Period from March 17, 2021 to October 11, 2021. Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary duties to the company.
On October 12, 2021, Value Investors Club issued a report alleging issues at Organogenesis Holdings, Inc., indicating that the wound care medical company has been improperly billing the federal government for $250 million annually. The Company also set the price for its new wound covering, Affinity, “exorbitantly high,” which Medicare reimbursed, while making the product lucrative for doctors to use through large rebates.
On this news, shares of Organogenesis fell over 18% in intraday trading on October 12, 2021.
If you are a long-term stockholder of Organogenesis, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is Bragar Eagel & Squire investigating?

They are investigating potential claims against Organogenesis Holdings for fiduciary breaches.

When was the class action complaint filed against Organogenesis?

The complaint was filed on December 10, 2021.

What allegations were made against Organogenesis?

Allegations include improper billing and exorbitant pricing for their wound care product.

How did Organogenesis' stock react to the allegations?

Shares fell over 18% in intraday trading on October 12, 2021.

How can stockholders contact Bragar Eagel & Squire?

They can reach out via email at investigations@bespc.com or call (212) 355-4648.

Last updated: Jan 2, 2024